Trials / Completed
CompletedNCT00922896
Trial of Erlotinib, Gemcitabine and Cisplatin in Metastatic Pancreatic Cancer
A Phase II Trial of Erlotinib in Combination With Gemcitabine and Cisplatin in Metastatic Pancreatic Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 22 (actual)
- Sponsor
- Gyeongsang National University Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the response rate of gemcitabine, cisplatin and erlotinib in metastatic pancreatic cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Gemcitabine, Cisplatin, Erlotinib (Tarceva) | * Erlotinib 100 mg po q d daily AND * Gemcitabine 1000 mg/m² with 250 mL of normal saline intravenously infusion over 30 mins on Day 1, 8 * Cisplatin 25 mg/m2 with 150 mL of normal saline intravenously infusion over 60 mins on D1,8 Every 3 weeks |
Timeline
- Start date
- 2009-06-01
- Primary completion
- 2010-08-01
- Completion
- 2011-05-01
- First posted
- 2009-06-17
- Last updated
- 2012-11-20
Locations
3 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT00922896. Inclusion in this directory is not an endorsement.